EA202091450A1 - Производные 2h-индазола в качестве ингибиторов cdk4 и cdk6 и их терапевтические применения - Google Patents

Производные 2h-индазола в качестве ингибиторов cdk4 и cdk6 и их терапевтические применения

Info

Publication number
EA202091450A1
EA202091450A1 EA202091450A EA202091450A EA202091450A1 EA 202091450 A1 EA202091450 A1 EA 202091450A1 EA 202091450 A EA202091450 A EA 202091450A EA 202091450 A EA202091450 A EA 202091450A EA 202091450 A1 EA202091450 A1 EA 202091450A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cdk4
inhibitors
therapeutic applications
indazole derivatives
cyclin
Prior art date
Application number
EA202091450A
Other languages
English (en)
Russian (ru)
Inventor
Майкл Николас Греко
Майкл Джон Костанцо
Цзижун Пэн
Дунь Чжан
Original Assignee
Бета Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бета Фарма, Инк. filed Critical Бета Фарма, Инк.
Publication of EA202091450A1 publication Critical patent/EA202091450A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202091450A 2018-01-29 2019-01-29 Производные 2h-индазола в качестве ингибиторов cdk4 и cdk6 и их терапевтические применения EA202091450A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862623516P 2018-01-29 2018-01-29
PCT/US2019/015547 WO2019148161A1 (en) 2018-01-29 2019-01-29 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
EA202091450A1 true EA202091450A1 (ru) 2021-01-14

Family

ID=67394794

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091450A EA202091450A1 (ru) 2018-01-29 2019-01-29 Производные 2h-индазола в качестве ингибиторов cdk4 и cdk6 и их терапевтические применения

Country Status (15)

Country Link
US (1) US11352341B2 (cg-RX-API-DMAC10.html)
EP (1) EP3746072B1 (cg-RX-API-DMAC10.html)
JP (1) JP7337395B2 (cg-RX-API-DMAC10.html)
KR (1) KR20200115583A (cg-RX-API-DMAC10.html)
CN (1) CN111989099A (cg-RX-API-DMAC10.html)
AU (1) AU2019211491B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020015405A2 (cg-RX-API-DMAC10.html)
CA (1) CA3088381A1 (cg-RX-API-DMAC10.html)
EA (1) EA202091450A1 (cg-RX-API-DMAC10.html)
IL (1) IL275948A (cg-RX-API-DMAC10.html)
MX (1) MX2020007959A (cg-RX-API-DMAC10.html)
PH (1) PH12020551155A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202006748RA (cg-RX-API-DMAC10.html)
TW (1) TW201940166A (cg-RX-API-DMAC10.html)
WO (1) WO2019148161A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2020527588A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. アデノシンアンタゴニストとしてのヘテロ環式化合物
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
AU2019289176B2 (en) * 2018-06-18 2026-02-19 Adelaide university Gremlin-1 antagonist for the prevention and treatment of cancer
WO2020150674A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
TW202521536A (zh) * 2019-05-05 2025-06-01 美商基尼特奇公司 Cdk抑制劑
US12570633B2 (en) 2020-06-22 2026-03-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Preparation method for CDK4/6 inhibitor
US20230416271A1 (en) * 2020-11-26 2023-12-28 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Heteroarylquinazoline compounds as protein kinase inhibitors
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
DE602004017474D1 (de) 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
JPWO2006008874A1 (ja) * 2004-05-21 2008-05-01 萬有製薬株式会社 アミノチアゾ−ル骨格を有するCdk4、6選択的阻害剤
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
AU2009284098B2 (en) * 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
RU2670762C2 (ru) * 2013-12-31 2018-10-25 Хуаньчжу Фарма Ко., Лтд. Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
WO2016014904A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
US9969719B2 (en) * 2015-03-11 2018-05-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
CN107286134B (zh) * 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2,4-二取代嘧啶衍生物作为cdk抑制剂及其应用

Also Published As

Publication number Publication date
CA3088381A1 (en) 2019-08-01
CN111989099A (zh) 2020-11-24
IL275948A (en) 2020-08-31
JP7337395B2 (ja) 2023-09-04
AU2019211491B2 (en) 2024-03-14
EP3746072B1 (en) 2023-04-12
EP3746072A4 (en) 2021-06-02
US11352341B2 (en) 2022-06-07
US20210139459A1 (en) 2021-05-13
EP3746072A1 (en) 2020-12-09
WO2019148161A1 (en) 2019-08-01
PH12020551155A1 (en) 2021-06-07
JP2021512161A (ja) 2021-05-13
SG11202006748RA (en) 2020-08-28
TW201940166A (zh) 2019-10-16
KR20200115583A (ko) 2020-10-07
BR112020015405A2 (pt) 2020-12-08
AU2019211491A1 (en) 2020-07-30
MX2020007959A (es) 2020-09-18

Similar Documents

Publication Publication Date Title
PH12020551155A1 (en) 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
EA201790122A1 (ru) Производные 2-h-индазола в качестве ингибиторов циклинзависимых киназ (cdk) и их терапевтическое применение
ECSP22011086A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PH12020551494A1 (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
JOP20220282A1 (ar) مركبات مفيدة لتثبيط كيناز ret
PH12022550015A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
JOP20230113A1 (ar) مشتقات ثلاثية الكربوكساميد كمثبطات prmt5
MX2023013082A (es) Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades.
MX391410B (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
MX2023013080A (es) Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
JOP20240235A1 (ar) مركبات أريل غير متجانسة لمعالجة الألم
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
AR066214A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
SA523451700B1 (ar) (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان
NO331166B1 (no) Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
CO2024015816A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2024013178A (es) Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades
GB201302704D0 (en) Therapeutic compounds
MX2025011886A (es) Derivados biciclicos semisaturados y usos relacionados
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
AR131414A1 (es) Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso